Brief: FDA Approved Mirdametinib, For Adult & Pediatric Patients 2 Years Of Age & Older With Nf1 Who Have Symptomatic Pn Not Amenable To Complete Resection

SpringWorks Therapeutics

11/02/2025 21:08

Feb 11 (Reuters) - 
  
    * FDA: APPROVED MIRDAMETINIB, FOR ADULT & PEDIATRIC PATIENTS
2
YEARS OF AGE & OLDER WITH NF1 WHO HAVE SYMPTOMATIC PN NOT
AMENABLE TO COMPLETE RESECTION


Further company coverage:  SWTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))